Efficacy of combination treatment with fingolimod (FTY720) plus pathogenic autoantigen in a glucose-6-phosphate isomerase peptide (GPI325-339)-induced arthritis mouse model.

Fingolimod (FTY720) is known to have a significant therapeutic effect in various autoimmune disease models. Here, we examined FTY720 in a model of rheumatoid arthritis, induced by immunizing DBA/1 mice with a peptide consisting of residues 325 through 339 of glucose-6-phosphate isomerase (GPI325-339). The efficacy was evaluated in terms of macroscopic findings, inflammatory cell infiltration and autoantibody level. Prophylactic administration of FTY720 from the day of immunization significantly suppressed the development of paw swelling, but therapeutic administration of FTY720 from onset of symptoms on day 8-9 was less effective. Interestingly, however, combination treatment with FTY720 plus GPI325-339 for 5 d after onset of symptoms significantly reduced the severity of symptoms in all mice, and no relapse occurred after booster immunization. Taking into account the reported mechanism of action of FTY720, these results indicate that combination treatment with FTY720 plus pathogenic autoantigen might efficiently induce immune tolerance by sequestering circulating autoantigen-specific lymphocytes from blood and peripheral tissues to the secondary lymphoid tissues. Combination treatment with FTY720 plus pathogenic autoantigen may become a breakthrough treatment for remission-induction in patients with autoimmune diseases including rheumatoid arthritis.

[1]  Yuya Yoshida,et al.  Therapeutic approach to steroid-resistant dermatitis using novel immunomodulator FTY720 (Fingolimod) in combination with betamethasone ointment in NC/Nga mice. , 2012, Biological & pharmaceutical bulletin.

[2]  Yuya Yoshida,et al.  Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, examined in non‐obese diabetic mice , 2012, Journal of diabetes investigation.

[3]  Yuya Yoshida,et al.  Therapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once‐daily injection of insulin glargine in non‐obese diabetic mice , 2011, Journal of diabetes investigation.

[4]  Thomas Kamradt,et al.  B Cell Depletion Reduces the Number of Autoreactive T Helper Cells and Prevents Glucose-6-Phosphate Isomerase-Induced Arthritis , 2011, PloS one.

[5]  Yuya Yoshida,et al.  Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen. , 2011, Biological & pharmaceutical bulletin.

[6]  L. Kappos,et al.  Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis , 2011, Neurology.

[7]  K. Miyazawa,et al.  Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. , 2010, Clinical immunology.

[8]  G. Verbruggen,et al.  A multiparameter approach to monitor disease activity in collagen-induced arthritis , 2010, Arthritis research & therapy.

[9]  S. Ito,et al.  B cells play a crucial role as antigen‐presenting cells and collaborate with inflammatory cytokines in glucose‐6‐phosphate isomerase‐induced arthritis , 2009, Clinical and experimental immunology.

[10]  S. Ito,et al.  Arthritogenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis , 2008, Arthritis research & therapy.

[11]  S. Ito,et al.  Therapeutic effects of antibodies to tumor necrosis factor-α, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis , 2008, Arthritis research & therapy.

[12]  T. Fujita,et al.  Synthesis of the key intermediate, diethyl 2-acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3-dioate, of the immunomodulatory agent FTY720 (fingolimod). , 2008, Chemical & pharmaceutical bulletin.

[13]  S. Ito,et al.  Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. , 2008, Arthritis and rheumatism.

[14]  R. Holmdahl,et al.  Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase , 2005, Arthritis research & therapy.

[15]  K. Watabe,et al.  A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice. , 2005, Biological & pharmaceutical bulletin.

[16]  T. Kamradt,et al.  The role and clinical implications of G6PI in experimental models of rheumatoid arthritis , 2004, Arthritis research & therapy.

[17]  K. Watabe,et al.  A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice. , 2004, Biological & pharmaceutical bulletin.

[18]  David Schubert,et al.  Immunization with Glucose-6-Phosphate Isomerase Induces T Cell-Dependent Peripheral Polyarthritis in Genetically Unaltered Mice1 , 2004, The Journal of Immunology.

[19]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[20]  E. Goetzl,et al.  The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[22]  T. Hanano,et al.  Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. , 2000, Journal of medicinal chemistry.

[23]  L. Feng,et al.  FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. , 2000, Trends in pharmacological sciences.

[24]  L. Joosten,et al.  IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. , 1999, Journal of immunology.

[25]  Kang,et al.  Intravenous tolerization with type II collagen induces interleukin‐4‐and interleukin‐10‐producing CD4+ T cells , 1999, Immunology.

[26]  M. Feldmann,et al.  Anti‐IL‐12 and anti‐TNF antibodies synergistically suppress the progression of murine collagen‐induced arthritis , 1999, European journal of immunology.

[27]  T. Kishimoto,et al.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. , 1998, Arthritis and rheumatism.

[28]  K. Sugahara,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. , 1998, Journal of immunology.

[29]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[30]  Edward F. Rosloniec,et al.  Collagen‐Induced Arthritis , 1996, Current protocols in immunology.

[31]  Richard O. Williams,et al.  Anti-CD4 monoclonal antibodies suppress murine collagen-induced arthritis only at the time of primary immunisation. , 1996, Cellular immunology.

[32]  T. Mak,et al.  Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. , 1996, Journal of immunology.

[33]  L. Joosten,et al.  Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. , 1996 .

[34]  F. Breedveld,et al.  T cell receptors in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[35]  D. Loh,et al.  Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.

[36]  T. Okumoto,et al.  Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. , 1994, The Journal of antibiotics.

[37]  S. Sriram,et al.  Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 , 1985, The Journal of experimental medicine.

[38]  S. Kerwar,et al.  Synergy between adjuvant arthritis and collagen-induced arthritis in rats , 1985, The Journal of experimental medicine.

[39]  F. Dixon,et al.  Serum transfer of collagen-induced arthritis in mice , 1983, The Journal of experimental medicine.

[40]  T. Takeuchi.  Revolutionary change in rheumatoid arthritis management with biological therapy. , 2011, The Keio journal of medicine.

[41]  Fujita,et al.  A Novel Immunomodulator , FTY 720 , Prevents Development of Experimental Autoimmune Myasthenia Gravis in C 57 BL / 6 Mice , 2005 .

[42]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.